Conjugation of the Recombinant Third Domain of Human Alpha-fetoprotein with Doxorubicin Using Poly(amidoamine) Dendrimers and Study of Its Cytotoxic Activity

S. I. Kisil, V. A. Chernikov, M. I. Danilevskiy, L. V. Savvateeva, N. V. Gorokhovets

Biochemistry department I.M. Sechenov First Moscow State Medical University Moscow, Russia.
esearch Institute of Uronephrology and Reproductive Health Care of the I. M. Sechenov First MSMU Moscow, Russia.
National Research Centre "Kurchatov Institute" Moscow, Russia.
Research Institute of Molecular Medicine of the I. M. Sechenov First MSMU Moscow, Russia.
Research Institute of Uronephrology and Reproductive Health Care of the I. M. Sechenov First MSMU Moscow, Russia.

DOI: 10.4236/eng.2012.410B021                

Abstract

The recombinant third domain of alpha-fetoprotein (AFP3D) is one of the promising vectors for targeted delivery of anticancer drugs to tumor cells. AFP3D-based conjugates with various anti-tumor agents have shown specific anti-tumor activity. The content of anti-tumor drugs in the preparation could be increased by including dendrimers - highly branched nanoparticles - into a targeted delivery system. In this study, we synthesized the AFP3D conjugate with doxorubicin-loaded poly(amidoamine) (PAMAM) dendrimer nanoparticles and investigated its cytotoxic activity. 

Keywords

Alpha-fetoprotein; Dendrimer; Doxorubicin; Targeted Delivery

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	B.F.Crandall, Alpha-fetoprotein, CRC Rev. Clin. Lab. Sci., vol. 15, pp. 127-185, 1981.
[2]	R. Chaturvedi, V. Agarkar, G. L. Sharma, P.U. Sarma, Purification of alpha-fetoprotein from human cord blood, Prep. Biochem. Biotechnol., pp. 293-303, April 1998.
[3]	H. F. Deutsch, Chemisry and Biology of α-fetoprotein, Adv. Cancer Res., vol.56, 1991, pp. 253-312.
[4]	S. Nishi, H. Hirai, Purification of human, dog and rabbit α-fetoprotein by immunoadsorbents of Sepharose coupled with anti-human α-fetoprotein, Biochim. Biophys. Acta, vol. 278, pp. 293-298, 1972.
[5]	R. Boismenu, D. Semeniuk, R. A. Murgita, Purification and characterization of human and mouse recombinant alpha-fetoproteins expressed in Escherichia coli, Protein Expression and Purif., vol. 10, pp.10-26, 1997.
[6]	Posypanova G. A., Gorokhovets N. V., Makarov V. A., Savvateeva L. V., Kireeva N. N., Severin S. E., Severin E. S., Recombinant alpha-fetoprotein C-terminal fragment: the new recombinant vector for targeted delivery. J Drug Target., vol.16, pp. 321-328, May 2008.
[7]	Savvateeva L. V., Gorokhovets N. V., Makarov V. A., Posypanova G. A., Severin S. E., Recombinant third domain of human alpha-fetoprotein: selectivity and antitumor activity of conjugate with Taxol. Abstracts of the XXXIII Meeting of the International Society for Oncodevelopmental Biology and Medicine (ISOBM), Rhodes, Greece, p. 84., September 2005.